Stock listing
TASE:EVGN Evogene Ltd. מניה
Israeli listing (TASE) of Evogene Ltd. · home listing NASDAQ:EVGN
Follow Evogene Ltd. into a list and get an email when it puts out news.
Share price · TASE:EVGN
100.20 ILA (agorot) -14.70 (-12.8%)
Close on Nov 19, 2026
- Day range
- 100.20 – 111.10 ILA (agorot)Nov 19, 2026
- Volume
- 104,056 sharesNov 19, 2026
- 52-week range
- 96.00 – 410.00 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- 105,940 ILSMedian day 57,453 shares · last 3 months, Aug 19, 2026 – Nov 5, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EVGN · Home | $0.316 USD | -0.034 (-9.7%) | 62,775 | $0.310 | $0.341 | $0.289 | $0.350 | Close on Nov 20, 2026 |
| TASE:EVGN | 100.20 ILA (agorot) | -14.70 (-12.8%) | 104,056 | 111.10 | 111.10 | 100.20 | 114.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 5, 2026 · TASE:EVGN · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 96.00 | -12.20 | -11.3% | 108.80 | 110.00 | 96.00 | 224,312 | |
| 108.20 | -2.80 | -2.5% | 112.60 | 113.10 | 108.20 | 7,116 | |
| 111.00 | -2.00 | -1.8% | 113.00 | 114.00 | 111.00 | 22,605 | |
| 113.00 | -0.10 | -0.1% | 116.20 | 117.10 | 111.90 | 55,132 | |
| 113.10 | -1.40 | -1.2% | 113.00 | 124.00 | 113.00 | 37,830 | |
| 114.50 | -3.30 | -2.8% | 117.00 | 120.00 | 114.50 | 12,260 | |
| 117.80 | +1.20 | +1.0% | 116.50 | 125.00 | 113.60 | 66,763 | |
| 116.60 | +3.40 | +3.0% | 113.20 | 121.60 | 113.20 | 73,987 | |
| 113.20 | -0.20 | -0.2% | 113.40 | 113.90 | 111.80 | 8,560 | |
| 113.40 | -3.20 | -2.7% | 115.90 | 115.90 | 110.00 | 57,453 | |
| 116.60 | +0.50 | +0.4% | 117.40 | 119.00 | 115.00 | 54,691 | |
| 116.10 | -0.30 | -0.3% | 119.60 | 120.00 | 116.10 | 66,273 | |
| 116.40 | -2.60 | -2.2% | 119.30 | 122.90 | 116.40 | 102,759 | |
| 119.00 | 0.00 | 0.0% | 121.00 | 121.00 | 116.60 | 78,333 | |
| 119.00 | -3.00 | -2.5% | 121.50 | 122.10 | 119.00 | 19,717 | |
| 122.00 | 0.00 | 0.0% | 125.20 | 127.00 | 117.10 | 39,709 | |
| 122.00 | +3.90 | +3.3% | 120.00 | 138.00 | 120.00 | 71,089 | |
| 118.10 | -4.50 | -3.7% | 122.00 | 122.00 | 118.10 | 71,870 | |
| 122.60 | +0.10 | +0.1% | 122.50 | 124.00 | 122.20 | 49,912 | |
| 122.50 | -2.90 | -2.3% | 125.40 | 125.40 | 120.20 | 38,727 | |
| 125.40 | +4.10 | +3.4% | 127.40 | 127.80 | 121.30 | 76,450 | |
| 121.30 | -3.70 | -3.0% | 123.90 | 123.90 | 120.00 | 197,355 | |
| 125.00 | +1.50 | +1.2% | 125.00 | 132.70 | 121.50 | 112,372 | |
| 123.50 | -4.60 | -3.6% | 126.00 | 126.00 | 121.00 | 93,252 | |
| 128.10 | +14.80 | +13.1% | 132.00 | 149.00 | 122.30 | 580,165 | |
| 113.30 | -21.70 | -16.1% | 137.70 | 164.60 | 113.30 | 311,774 | |
| 135.00 | -4.00 | -2.9% | 136.40 | 139.90 | 133.00 | 25,699 | |
| 139.00 | -7.00 | -4.8% | 144.90 | 144.90 | 134.00 | 85,641 | |
| 146.00 | -1.80 | -1.2% | 145.60 | 146.90 | 142.30 | 90,940 | |
| 147.80 | -5.20 | -3.4% | 154.00 | 154.00 | 142.00 | 152,737 | |
| 153.00 | 0.00 | 0.0% | 153.10 | 154.60 | 150.90 | 60,897 | |
| 153.00 | -3.50 | -2.2% | 158.10 | 167.90 | 152.70 | 82,777 | |
| 156.50 | +8.50 | +5.7% | 145.00 | 160.60 | 145.00 | 131,260 | |
| 148.00 | -4.00 | -2.6% | 150.50 | 163.90 | 139.00 | 48,646 | |
| 152.00 | -4.50 | -2.9% | 154.80 | 155.00 | 147.00 | 87,192 | |
| 156.50 | -0.80 | -0.5% | 159.00 | 160.10 | 152.00 | 16,551 | |
| 157.30 | -6.70 | -4.1% | 163.00 | 163.20 | 154.10 | 72,502 | |
| 164.00 | -7.00 | -4.1% | 158.00 | 164.20 | 157.90 | 158,105 | |
| 171.00 | +9.90 | +6.1% | 172.00 | 173.10 | 167.50 | 49,286 | |
| 161.10 | -1.60 | -1.0% | 168.00 | 168.00 | 161.10 | 26,775 | |
| 162.70 | +1.70 | +1.1% | 162.00 | 166.00 | 162.00 | 20,098 | |
| 161.00 | -0.10 | -0.1% | 166.20 | 167.40 | 159.20 | 62,621 | |
| 161.10 | +0.80 | +0.5% | 160.30 | 170.00 | 160.30 | 31,324 | |
| 160.30 | -2.50 | -1.5% | 161.00 | 163.00 | 158.00 | 36,058 | |
| 162.80 | +0.30 | +0.2% | 163.00 | 165.00 | 161.20 | 27,700 | |
| 162.50 | -3.50 | -2.1% | 168.90 | 171.30 | 160.90 | 48,194 | |
| 166.00 | -5.50 | -3.2% | 172.80 | 172.80 | 165.30 | 32,361 | |
| 171.50 | -1.50 | -0.9% | 173.30 | 175.70 | 171.50 | 45,655 | |
| 173.00 | -6.50 | -3.6% | 179.50 | 179.50 | 171.00 | 32,101 | |
| 179.50 | +7.00 | +4.1% | 177.50 | 181.90 | 177.50 | 62,975 | |
| 172.50 | +2.70 | +1.6% | 169.80 | 178.00 | 169.80 | 39,678 |
Splits
2 splits since 2013 · TASE:EVGN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-2 | Consolidation |
- Ticker
- TASE:EVGN
- Asset type
- Stock
- Exchange
- TASE
- Currency
- ILA
What changed lately
Latest news release · Nov 19, 2026
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
Latest earnings call · Nov 19, 2026
Evogene (NASDAQ:EVGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 27, 2026
Investor Presentation (August 2026)
Investor deck · 32 slides
Latest news
Evogene Schedules Third Quarter 2026 Financial Results Release
Nov 5, 2026
Closed 96.00 (-11.3%) on Nov 5, 2026
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Oct 28, 2026
Closed 117.80 (+1.0%) on Oct 28, 2026
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Oct 26, 2026
Closed 116.60 (+3.0%) on Oct 26, 2026
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
Oct 20, 2026
Closed 116.10 (-0.3%) on Oct 20, 2026
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Oct 6, 2026
Closed 125.40 (+3.4%) on Oct 7, 2026
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Sep 30, 2026
Closed 128.10 (+13.1%) on Sep 30, 2026
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Aug 31, 2026
Closed 161.10 (+0.5%) on Aug 31, 2026
Evogene Ltd. on 6ix
- News releases
- 36 in the last 12 months · 114 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 28 calls with a replay · 28 with a transcript · latest Nov 19, 2026
- Decks
- 53 decks · latest Aug 27, 2026
Where Evogene Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EVGN · Home listing | NASDAQ | United States | USD |
| TASE:EVGN · This page | TASE | Israel | ILA |
| BOATS:EVGN | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.06M USD
- P/E
- Loss
- EV/sales
- −2.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −166.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.39
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.15 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.10 · 1 analyst
- Revenue, year to Dec 2026
- 1.44M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Richard Novak | CEO, Unravel Biosciences |
| Sven Wichert | CEO of Systasy Bioscience |
Board
| Director | Role |
|---|---|
| Nir Nimrodi | Chairperson of the Board |
| Adrian Percy | Board Member |
| Dan Falk | Board Member |
| Leon Recanati | Board Member |
| Ofer Haviv | Board Member |
| Sarit Firon | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Evogene (NASDAQ:EVGN) Q3 2026 Earnings Call | Thu, Nov 19, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2026 Earnings Call | Tue, Aug 18, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q1 2026 Earnings Call | Wed, May 20, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q3 2025 Earnings Call | Thu, Nov 20, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2025 Earnings Call | Tue, Aug 19, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q1 2025 Earnings Call | Wed, May 21, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q4 2024 Earnings Call | Thu, Mar 06, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q3 2024 Earnings Call | Thu, Nov 21, 2024 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2024 Earnings Call | Thu, Aug 22, 2024 · 9:00 AM ET | Replay |
All 28 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 19, 2026 · Before open | −9.7% |
| Q2 2026 | Aug 18, 2026 · Before open | +3.6% |
| Q1 2026 | May 20, 2026 · Before open | −2.7% |
| Q4 2025 | Mar 5, 2026 | −8.3% |
| Q3 2025 | Nov 20, 2025 · Before open | −7.7% |
| Q2 2025 | Aug 19, 2025 · Before open | −4.5% |
| Q1 2025 | May 21, 2025 · Before open | −6.3% |
| Q4 2024 | Mar 5, 2025 · After close | 0.0% |
| Q3 2024 | Nov 21, 2024 · Before open | −3.0% |
| Q2 2024 | Aug 22, 2024 · Before open | −10.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 23, 2024 · Before open | −2.7% |
| Q4 2023 | Mar 7, 2024 · Before open | +3.2% |
| Q3 2023 | Nov 15, 2023 · Before open | +4.8% |
| Q2 2023 | Aug 17, 2023 · Before open | −19.2% |
| Q1 2023 | May 18, 2023 · Before open | −4.5% |
| Q4 2022 | Mar 9, 2023 · Before open | −4.2% |
| Q3 2022 | Nov 17, 2022 · Before open | +1.4% |
| Q2 2022 | Aug 31, 2022 · Before open | −13.3% |
| Q1 2022 | May 26, 2022 · Before open | −8.2% |
| Q4 2021 | Mar 10, 2022 · Before open | +7.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 32 slides | Aug 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 18 slides | Aug 18, 2026 |
| Investor Presentation (June 2026) | Investor deck | 32 slides | Jun 16, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 27 slides | May 20, 2026 |
| Investor Presentation (April 2026) | Investor deck | 27 slides | Apr 28, 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | Mar 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 18 slides | Mar 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 7, 2026 |
| Investor Presentation (November 2025) | Investor deck | 28 slides | Nov 27, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 34 slides | Nov 20, 2025 |
Show 50 decks
This page holds 50 of 53 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Warrant exercise of ordinary shares on exercise of August 2024 Series A and Series B warrants Announced: about US$3.4M · US$1 a share · Warrants at US$1.25 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Use of proceeds: Working capital and other general corporate purposes | Feb 10, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.75 a share on Nov 20, 2013.
- Price
- US$14.75 a share
- Shares offered
- 5,000,000 ordinary shares
- Offering size
- US$73.8 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- Credit Suisse, Deutsche Bank Securities, Oppenheimer & Co., Piper Jaffray · In the order on the cover
- Shares delivered
- On or about Nov 26, 2013
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 26, 2013 |
| Filed publicly | Sep 23, 2013 |
| Amended 6 times | Newest Nov 19, 2013 |
| Shares registered with an exchange | Nov 8, 2013 |
| Declared effective by the SEC | Nov 20, 2013 |
| Final prospectus, with the price | Nov 22, 2013 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 22, 2013 |
| EFFECT · Notice that a registration is effective | Nov 20, 2013 |
| F-1/A · Registration statement, amended | Nov 19, 2013 |
| CORRESP · Letter to the SEC | Nov 18, 2013 |
| F-1/A · Registration statement, amended | Nov 15, 2013 |
| UPLOAD · Letter from the SEC | Nov 15, 2013 |
| CERTNYS · New York Stock Exchange's certificate of listing | Nov 12, 2013 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 8, 2013 |
| CORRESP · Letter to the SEC | Nov 6, 2013 |
| F-1/A · Registration statement, amended | Nov 6, 2013 |
All 30 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Nov 6, 2013 |
| F-1/A · Registration statement, amended | Oct 31, 2013 |
| CORRESP · Letter to the SEC | Oct 28, 2013 |
| F-1/A · Registration statement, amended | Oct 28, 2013 |
| UPLOAD · Letter from the SEC | Oct 21, 2013 |
| CORRESP · Letter to the SEC | Oct 11, 2013 |
| F-1/A · Registration statement, amended | Oct 11, 2013 |
| UPLOAD · Letter from the SEC | Oct 7, 2013 |
| F-1 · Registration statement | Sep 23, 2013 |
| UPLOAD · Letter from the SEC | Sep 5, 2013 |
| DRSLTR · Letter to the SEC with a draft | Aug 22, 2013 |
| DRS/A · Draft registration statement, amended | Aug 22, 2013 |
| UPLOAD · Letter from the SEC | Jul 24, 2013 |
| DRSLTR · Letter to the SEC with a draft | Jul 11, 2013 |
| DRS/A · Draft registration statement, amended | Jul 11, 2013 |
| UPLOAD · Letter from the SEC | Jun 18, 2013 |
| DRSLTR · Letter to the SEC with a draft | Jun 3, 2013 |
| DRS/A · Draft registration statement, amended | Jun 3, 2013 |
| UPLOAD · Letter from the SEC | May 23, 2013 |
| DRS · Draft registration statement | Apr 26, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 22, 2013
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.85M | 5.58M | 2.98M | 1.68M | 930.0K | 1.04M | 753.0K | 1.75M | 3.38M | 6.54M |
| Cost of revenue | 4.09M | 2.38M | 1.49M | 909.0K | 767.0K | 574.0K | 334.0K | 1.45M | 2.85M | 5.64M |
| Gross profit | -241.0K | 3.20M | 1.49M | 766.0K | 163.0K | 466.0K | 419.0K | 295.0K | 536.0K | 901.0K |
| Research and development | 7.99M | 12.5M | 16.2M | 20.8M | 21.1M | 17.3M | 15.8M | 14.7M | 17.0M | 16.4M |
| Selling, general and administrative | 4.29M | 6.99M | 5.38M | 6.48M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M |
| Operating income | -14.0M | -18.8M | -22.2M | -26.9M | -31.0M | -24.8M | -21.2M | -20.0M | -21.9M | -21.1M |
| Depreciation and amortization | 1.14M | 1.38M | 1.30M | 1.51M | 1.30M | 1.79M | 2.40M | 2.02M | 2.15M | 2.28M |
| EBITDA | -12.9M | -17.4M | -20.9M | -25.4M | -29.7M | -23.0M | -18.8M | -18.0M | -19.8M | -18.8M |
| Interest expense | 1.93M | 3.36M | 928.0K | 3.33M | 1.41M | 2.95M | 555.0K | 2.21M | 1.00M | 891.0K |
| Income before tax | -13.5M | -14.8M | -21.9M | -29.8M | -30.4M | -26.2M | -19.1M | -20.8M | -20.8M | -19.6M |
| Income tax | 1.00K | 9.00K | 19.0K | 90.0K | 13.0K | 32.0K | 24.0K | 30.0K | 11.0K | 36.0K |
| Net income | -8.48M | -16.5M | -23.9M | -26.6M | -27.8M | -23.4M | -18.1M | -20.8M | -20.8M | -19.6M |
| Earnings per share, basic | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 | -0.83 | -0.70 | -0.81 | -0.81 | -0.77 |
| Earnings per share, diluted | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 | -0.83 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 13.0M | 15.3M | 20.8M | 29.0M | 32.3M | 46.2M | 34.7M | 5.81M | 3.44M | 3.24M |
| Short-term investments | 32.0K | 10.0K | 10.3M | 6.38M | 21.5M | 2.00M | 12.1M | 48.7M | 68.3M | 84.9M |
| Receivables | 317.0K | 1.09M | 357.0K | 348.0K | 281.0K | 222.0K | 72.0K | 160.0K | 132.0K | 169.0K |
| Inventory | 210.0K | 1.82M | 76.0K | 566.0K | 92.0K | 0 | -894.0K | -444.0K | -8.33M | -13.1M |
| Current assets | 15.6M | 21.6M | 34.5M | 37.8M | 56.9M | 51.8M | 49.0M | 55.5M | 72.8M | 89.5M |
| Property, plant and equipment | 812.0K | 1.80M | 2.46M | 2.50M | 2.07M | 2.07M | 2.58M | 3.19M | 4.79M | 6.48M |
| Total assets | 20.0M | 39.9M | 51.1M | 56.1M | 76.3M | 71.9M | 71.4M | 58.7M | 77.6M | 96.0M |
| Accounts payable | 639.0K | 1.23M | 1.78M | 1.04M | 1.46M | 863.0K | 1.00M | 1.01M | 1.11M | 1.33M |
| Current liabilities | 3.44M | 18.7M | 6.94M | 5.63M | 6.88M | 9.68M | 5.75M | 5.43M | 4.66M | 5.22M |
| Long-term debt | 10.4M | 10.1M | ||||||||
| Total debt | 2.20M | 12.9M | 11.5M | 11.9M | 2.67M | 2.44M | 2.97M | |||
| Total liabilities | 8.07M | 25.0M | 22.4M | 21.3M | 12.9M | 15.0M | 11.1M | 8.39M | 8.22M | 8.70M |
| Shareholders' equity | -82.0K | -1.45M | 12.1M | 27.9M | 53.7M | 46.0M | 50.1M | 50.1M | 69.4M | 87.3M |
| Shares outstanding | 8.72M | 6.51M | 5.08M | 41.3M | 41.2M | 35.6M | 25.8M | 25.8M | 25.8M | 25.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.5M | -19.7M | -21.6M | -23.7M | -24.7M | -19.5M | -17.7M | -15.2M | -15.9M | -11.7M |
| Capital spending | -135.0K | -626.0K | -577.0K | -1.17M | -847.0K | -682.0K | -900.0K | -374.0K | -590.0K | -808.0K |
| Free cash flow | -13.6M | -20.3M | -22.2M | -24.8M | -25.6M | -20.2M | -18.6M | -15.5M | -16.5M | -12.5M |
| Cash from investing | 17.7M | 9.62M | -4.54M | 13.3M | -20.6M | 9.41M | 37.1M | 17.4M | 15.2M | 4.03M |
| Cash from financing | -6.60M | 4.66M | 18.2M | 9.34M | 30.3M | 20.4M | 9.31M | 297.0K | 814.0K | 655.0K |
| Share buybacks | 10.0M | 9.00K | 683.0K | 186.0K | ||||||
| Change in cash | -2.35M | -5.47M | -8.21M | -3.35M | -13.9M | 11.5M | 28.9M | 2.38M | 199.0K | -6.99M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 6, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 467 filings. Open Filings
Cap table
Built by 6ix from Evogene Ltd.’s releases · as of Sep 30, 2026
- Common shares
- 13,586,507
- Fully diluted
- 13,586,507
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 13,586,507 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,586,507 |
| Sep 30, 2026 | 18,052,405 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dan Falk Other companies: Innoviz Technologies Ltd. (Director · Since at least Mar 18, 2026); NICE Ltd. (Director · Since at least Mar 18, 2026) | Board Member · Since at least Mar 18, 2026 |
| Nir Nimrodi Other companies: Odysight.ai Inc. (Director · Since at least Feb 10, 2025); Precigen, Inc. (Chief Business Officer · Mar 17, 2014 – Jan 4, 2019 · Past) | Chairperson of the Board · Since at least Mar 18, 2026 |
| Leon Recanati Other companies: Kamada Ltd. (Director · Since at least Mar 16, 2026) | Board Member · Since at least Mar 18, 2026 |
| Sarit Firon Other companies: MediaMind Technologies Inc (Chief Financial Officer · Aug 10, 2010 – Aug 10, 2010 · Past) | Board Member · Since at least Mar 6, 2025 |
| Yaron Eldad Other companies: Freightos Limited (Chief Financial Officer · Since at least Aug 17, 2026) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Adrian Percy | Board Member · Since at least Mar 18, 2026 |
| Gabi Tarcic | Chief Development Officer · Since at least Mar 18, 2026 |
| Ilia Zhidkov | Chief Technology Officer · Since at least Mar 18, 2026 |
| Ofer Haviv | Board Member · Since at least Mar 18, 2026 |
| Olga Nissan | Vice President of Business Development · Dec 30, 2025 – Nov 5, 2026 · Past |
All 13 people
| Person | Seat |
|---|---|
| Polina Ravzin | VP Finance · Since at least Apr 1, 2026 |
| Richard Novak | CEO, Unravel Biosciences · Since at least Jan 7, 2026 |
| Sven Wichert | CEO of Systasy Bioscience · Since at least Feb 11, 2026 |
Log in to ask 6ix AI your own questions about Evogene Ltd.